Craft

BioLineRx

Stock Price

$0.4

2024-10-29

Market Capitalization

$38.5 M

2024-10-29

Revenue

$1.2 M

FY, 2025

BioLineRx Summary

Company Summary

Overview
BioLineRx is a biopharmaceutical company focused on oncology. It in-licenses compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for clinical development and/or commercialization. The company provides therapeutic candidates for stem cell mobilization, pancreatic cancer, AML (acute myeloid leukemia), gastric cancer, and solid tumors.
Type
Public
Status
Active
Founded
2003
HQ
Modi'in-Maccabim-Re'ut, IL | view all locations
Website
https://www.biolinerx.com/
Cybersecurity rating
Sectors

Key People

  • Aharon Schwartz, Chairman

    • Philip A. Serlin

      Philip A. Serlin, Chief Executive Officer

      • Michael J. Anghel, Director

        • Rafael Hofstein, Director

          LocationsView all

          1 location detected

          • Modi'in-Maccabim-Re'ut, Center District HQ

            Israel

            Technology Park, HaMa'ayan St 44

          BioLineRx Financials

          Summary Financials

          Revenue (FY, 2025)
          $1.2M
          Gross profit (FY, 2025)
          $950.0K
          Net income (FY, 2025)
          ($2.0M)
          Cash (FY, 2025)
          $3.3M
          EBIT (FY, 2025)
          ($11.6M)
          Enterprise value
          $45.0M

          Footer menu